1. Home
  2. SIGI vs COGT Comparison

SIGI vs COGT Comparison

Compare SIGI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Selective Insurance Group Inc.

SIGI

Selective Insurance Group Inc.

HOLD

Current Price

$73.08

Market Cap

5.2B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$36.87

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIGI
COGT
Founded
1926
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.0B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SIGI
COGT
Price
$73.08
$36.87
Analyst Decision
Hold
Strong Buy
Analyst Count
5
15
Target Price
$84.40
$36.21
AVG Volume (30 Days)
399.1K
1.6M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,871,000.00
Revenue This Year
$3.69
N/A
Revenue Next Year
$4.75
$1,581.80
P/E Ratio
$11.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$71.75
$3.72
52 Week High
$93.38
$43.73

Technical Indicators

Market Signals
Indicator
SIGI
COGT
Relative Strength Index (RSI) 25.48 52.64
Support Level $72.60 $36.52
Resistance Level $80.39 $41.02
Average True Range (ATR) 1.66 1.72
MACD -0.28 0.01
Stochastic Oscillator 6.04 79.14

Price Performance

Historical Comparison
SIGI
COGT

About SIGI Selective Insurance Group Inc.

Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: